Form 4: Emergent BioSolutions SVP Sells Shares for Tax

Emergent BioSolutions SVP William Hartzel reported a future disposal of 610 common shares on November 11, 2025, to cover tax obligations from restricted stock unit vesting.

Summary

• William Hartzel, SVP, Bioservices at Emergent BioSolutions Inc. (EBS), reported a transaction involving the company's common stock.
• The transaction entails the disposal of 610 shares of common stock.
• The shares were disposed of on November 11, 2025, at a price of $10.88 per share.
• This disposal represents shares withheld to pay taxes associated with the vesting and settlement of restricted stock units.
• Following this reported transaction, Mr. Hartzel beneficially owns 103,082 shares of common stock directly.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider transaction for tax purposes, which is neutral in sentiment regarding the company's performance or outlook.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report reflects a routine equity compensation event for an executive, which is common across various industries, including biotechnology and pharmaceuticals. It does not provide broader insights into industry trends or competitive landscape.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, pre-planned transaction for tax purposes by an executive, not indicative of a change in company fundamentals or strategy.

Key Dates

Keywords

Emergent BioSolutions, EBS, William Hartzel, Insider Transaction, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, 10b5-1 Plan, Biotechnology, Pharmaceuticals